CA2439559A1 - Technique de determination de pronostic post therapeutique d'un cancer de la prostate - Google Patents

Technique de determination de pronostic post therapeutique d'un cancer de la prostate Download PDF

Info

Publication number
CA2439559A1
CA2439559A1 CA002439559A CA2439559A CA2439559A1 CA 2439559 A1 CA2439559 A1 CA 2439559A1 CA 002439559 A CA002439559 A CA 002439559A CA 2439559 A CA2439559 A CA 2439559A CA 2439559 A1 CA2439559 A1 CA 2439559A1
Authority
CA
Canada
Prior art keywords
igfbp
tgf
patients
prostate cancer
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439559A
Other languages
English (en)
Inventor
Kevin M. Slawin
Shahrokh Shariat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439559A1 publication Critical patent/CA2439559A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Abstract

La présente invention concerne une technique permettant de déterminer un pronostic pour des patients atteint d'un cancer de la prostate, par exemple un cancer de la prostate cliniquement localisé.
CA002439559A 2001-02-07 2002-02-07 Technique de determination de pronostic post therapeutique d'un cancer de la prostate Abandoned CA2439559A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26697601P 2001-02-07 2001-02-07
US60/266,976 2001-02-07
US60/295,498 2001-06-01
US60/295,692 2001-06-04
PCT/US2002/003569 WO2002068960A1 (fr) 2001-02-07 2002-02-07 Technique de determination de pronostic post therapeutique d'un cancer de la prostate

Publications (1)

Publication Number Publication Date
CA2439559A1 true CA2439559A1 (fr) 2002-09-06

Family

ID=23016780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439559A Abandoned CA2439559A1 (fr) 2001-02-07 2002-02-07 Technique de determination de pronostic post therapeutique d'un cancer de la prostate

Country Status (3)

Country Link
EP (1) EP1373899A1 (fr)
CA (1) CA2439559A1 (fr)
WO (1) WO2002068960A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235816A1 (en) * 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
AU2012212075A1 (en) * 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
WO2019118443A1 (fr) * 2017-12-11 2019-06-20 Georgetown University Biomarqueurs prédictifs d'effets secondaires de radiothérapie
IT201800021394A1 (it) * 2018-12-28 2020-06-28 Daniela Terracciano Metodo in vitro per la diagnosi del cancro alla prostata

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1057026A4 (fr) * 1998-01-21 2005-10-05 Brigham & Womens Hospital Facteur de croissance insulunoide i circulant et risque de developpement d'un cancer prostatique
EP1175661B1 (fr) * 1999-04-21 2006-11-02 SPSS, Inc. Procede informatique et appareil permettant de creer des graphiques visibles par utilisation d'une algebre de graphe

Also Published As

Publication number Publication date
EP1373899A1 (fr) 2004-01-02
WO2002068960A1 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
US20030235816A1 (en) Method to determine outcome for patients with prostatic disease
Nossov et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Bostwick et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
Borgoño et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer
US8772038B2 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
US7592145B2 (en) Pin 1 as a marker for prostate cancer
Andres et al. Expression of urokinase‐type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI‐1) in human breast carcinomas and their clinical relevance
US20050282199A1 (en) Method to predict prostate cancer
CN111679072B (zh) Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用
Yin et al. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer
Gettman et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma
Xiang et al. Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma
Karam et al. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer
Srdelić Mihalj et al. Lipocalin‐2 and matrix metalloproteinase‐9 expression in high‐grade endometrial cancer and their prognostic value
Diez et al. Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue
Josefsson et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment
Shariat et al. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy
Zhu et al. CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance
Gonzalez et al. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy
Thomas et al. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma.
US20030054419A1 (en) Method to determine prognosis after therapy for prostate cancer
CA2439559A1 (fr) Technique de determination de pronostic post therapeutique d'un cancer de la prostate
Kuvaja et al. High serum TIMP-1 correlates with poor prognosis in breast carcinoma–a validation study
Hagiwara et al. Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma
Tan et al. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued